1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. c-Met/HGFR

c-Met/HGFR

c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.

c-Met/HGFR Related Products (49):

Cat. No. Product Name Effect Purity
  • HY-13016
    Cabozantinib Inhibitor 99.92%
    Cabozantinib is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
  • HY-50878
    Crizotinib Inhibitor 99.97%
    Crizotinib is a potent inhibitor of c-Met and ALK with an IC50 of 11 nM and 24 nM in cell-based assays, respectively.
  • HY-13404
    Capmatinib Inhibitor 99.84%
    Capmatinib (INCB28060) is a potent and selective c-MET kinase inhibitor. Capmatinib (INCB28060) inhibits c-MET kinase activity with an average IC50 of 0.13 nM.
  • HY-10338
    Foretinib Inhibitor 99.81%
    Foretinib is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
  • HY-11107
    PHA-665752 Inhibitor
    PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with an IC50 of 9 nM.
  • HY-111787
    CSF1R-IN-2 Inhibitor
    CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.
  • HY-116000
    Glumetinib Inhibitor
    Glumetinib (SCC244) is a potent and highly selective c-Met kinase inhibitor with an IC50 of 0.42 nM. Glumetinib shows antitumor activity and a superior safety margin.
  • HY-12423A
    TAS-115 mesylate Inhibitor 99.15%
    TAS-115 mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
  • HY-16969
    Dihexa Activator >98.0%
    Dihexa is an orally active, blood-brain barrier-permeable angiotensin IV analog; exhibits high affinity binding hepatocyte growth factor (HGF) with a Kd of 65 pM.
  • HY-15959
    Savolitinib Inhibitor 98.45%
    Savolitinib (AZD6094) ia highly potent and selective c-Met inhibitor with an IC50 of 5 nM.
  • HY-50686
    Tivantinib Inhibitor 99.39%
    Tivantinib is a novel and highly selective c-Met tyrosine kinase inhibitor with Ki of 355 nM.
  • HY-12076
    BMS 777607 Inhibitor 99.48%
    BMS 777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases.
  • HY-50878A
    Crizotinib hydrochloride Inhibitor 99.86%
    Crizotinib hydrochloride is a potent inhibitor of c-Met and ALK with IC50s of 11 nM and 24 nM in cell-based assays, respectively.
  • HY-14721
    Tepotinib Inhibitor 99.80%
    Tepotinib (EMD-1214063) is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.
  • HY-15514
    Merestinib Inhibitor 99.99%
    Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM.
  • HY-100946
    CEP-40783 Inhibitor 98.25%
    CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.
  • HY-50683
    JNJ-38877605 Inhibitor 99.95%
    JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.
  • HY-B0791
    Altiratinib Inhibitor
    Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC50s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3 respectively.
  • HY-12014
    SU11274 Inhibitor 98.09%
    SU11274 is a selective Met inhibitor with IC50 of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.
  • HY-16590
    X-376 Inhibitor 98.36%
    X-376 is a potent and dual ALK/MET inhibitor with IC50s of 0.61 nM and 0.69 nM, respectively.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.